Abstract:Aim: Cancer as a complex disease poses significant challenges for both diagnosis and treatment. Researchers have been exploring various avenues to find effective therapeutic strategies, with a particular emphasis on cellular signaling pathways and immunotherapy. One such pathway that has recently been suggested is the PD-1/PD-L1 pathway, which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis. Cancer cells exploit this pathway by producing PD-L1, which attaches to PD-1 on T cells, thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system. This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment. Method: This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). All in vitro , in vivo , and clinical studies that were published in English have been considered during a thorough search of the Scopus, Web of Science, and PubMed databases without date restriction until March 2024. Results: According to the studies reviewed, the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, squamous cell carcinoma, and colorectal cancer, among others. Additionally, research suggests that immune checkpoint inhibitors that block PD1/PD-L1, such as pembrolizumab, atezolizumab, nivolumab, durvalumab, cemiplimab, avelumab, etc. , can effectively prevent tumor cells from escaping the immune system. Moreover, there might be a possible interaction between microbiome, obesity, etc. on immune mechanisms and on the immune checkpoint inhibitors (ICIs). Conclusion: Although we have gained considerable knowledge about ICIs, we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients. This is largely due to the complex interactions between different intracellular pathways, which need to be thoroughly studied. To resolve this issue, it is necessary to conduct more reliable clinical trials that can produce a scientific consensus.

PI3K/AKT/mTOR and PD‐1/CTLA‐4/CD28 pathways as key targets of cancer immunotherapy (Review)

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Tumor Immune Checkpoints and Their Associated Inhibitors

A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

PD-1/PD-L1 pathway: current researches in cancer.

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

PD-1 regulation in immune homeostasis and immunotherapy